Projekt

ODM-201 maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with one novel hormonal agent first line and non-progressive disease after second line treatment with a taxane: A multicenter randomized double-blind placebo-controlled phase II trial

Abgeschlossen · 2017 bis 2024

Fischer Stefanie, Harder Anja, Quinter Janine